RENEO PHARMACEUTICALS INC (RPHM)

Company Profile

Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company is headquartered in Irvine, California and currently employs 55 full-time employees. The company went IPO on 2021-04-09. The firm is focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). The firm's product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARd). Mavodelpar helps in increasing the transcription of genes involved in mitochondrial function and increases fatty acid oxidation (FAO) and may increase the production of new mitochondria. The firm is developing REN001 in the two rare genetic diseases that present with myopathy and have unmet medical needs: primary mitochondrial myopathies (PMM), and long-chain fatty acid oxidation disorders (LC-FAOD).

Company Info

RENEO PHARMACEUTICALS INC

18575 Jamboree Road, Suite 275-S

Irvine CALIFORNIA

P: 18582830280

Employees: 55

Website: https://reneopharma.com/